RBC Capital Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Leonid Timashev maintains an Outperform rating on Edgewise Therapeutics (NASDAQ:EWTX) and raises the price target from $28 to $32.
April 22, 2024 | 3:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has maintained its Outperform rating on Edgewise Therapeutics and increased the price target from $28 to $32.
The increase in the price target by a reputable analyst like Leonid Timashev from RBC Capital is a strong positive signal for Edgewise Therapeutics. It suggests confidence in the company's future performance and growth prospects, likely leading to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100